Aoda Shengwu
Latest round
- Series A
Last raised
- Aug 2025
Total raised
- $4.2M
Investors
- 1
About Aoda Shengwu
Founded in 2017 and based in Chengdu, China, Aoda Shengwu operates as a biopharmaceutical company that focuses on the research and development of targeted peptide drugs. It was recognized as the National High-tech Enterprise in 2021. The company has applied for more than 50 invention patents and has been authorized 14 invention patents. The company established a laboratory and established a research and development pipeline in 2018. In June 2024, Aoda Shengwu closed a strategic investment. Aoda Shengwu mainly engages in the research, development, production, and sales of targeted peptide drugs. It currently has 15 products, including drugs for type II diabetes, broad-spectrum coronavirus membrane fusion inhibitors, peptide vaccines for multiple myeloma, etc. Products can be used in the treatment of diabetes, coronavirus, and other diseases. The company generates revenue by selling targeted peptide drugs.
Who invested in Aoda Shengwu
1 investor across 1 round
See all investors in Aoda Shengwu
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 9, 2025
Amount
$4.2M
Investors
Questions about Aoda Shengwu
Who invested in Aoda Shengwu?
Aoda Shengwu has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aoda Shengwu raised?
Aoda Shengwu has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Aoda Shengwu last raise money?
Aoda Shengwu's most recent round on record is a Series A, in Aug 2025.
What does Aoda Shengwu do?
Founded in 2017 and based in Chengdu, China, Aoda Shengwu operates as a biopharmaceutical company that focuses on the research and development of targeted peptide drugs.
Where is Aoda Shengwu headquartered?
Aoda Shengwu is headquartered in Chengdu, China.
Which VCs invest in companies like Aoda Shengwu?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Aoda Shengwu's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Aoda Shengwu? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.